journal article·2023-08-30

Photothermal and Acid-Responsive Fucoidan-CuS Bubble Pump Microneedles for Combined CDT/PTT/CT Treatment of Melanoma

Jiaojiao Tao, Bingjie Wang, Yu Dong, XiangYan Chen, Shuang Li, Tianze Jiang, Xia Zhao

ACS Applied Materials & Interfaces· Volume 15· Issue 34
Publisher page

Abstract

Transdermal cancer therapy faces great challenges in clinical practice due to the low drug transdermal efficiency and the unsatisfactory effect of monotherapy. Herein, we develop a novel bubble pump microneedle system (BPMN-CuS/DOX) by embedding sodium bicarbonate (NaHCO 3 ) into hyaluronic acid microneedles (MNs) loaded with fucoidan-based copper sulfide nanoparticles (Fuc-CuS NPs) and doxorubicin (DOX). BPMN-CuS/DOX can generate CO 2 bubbles triggered by an acidic tumor microenvironment for deep and rapid intradermal drug delivery. Fuc-CuS NPs exhibit excellent photothermal effect and Fenton-like catalytic activity, producing more reactive oxygen species (ROS) by photothermal therapy (PTT) and chemodynamic therapy (CDT), which enhances the antitumor efficacy of DOX and reduces the dosage of its chemotherapy (CT). Simultaneously, DOX increases intracellular hydrogen peroxide (H 2 O 2 ) supplementation and promotes the sustained production of ROS. BPMN-CuS/DOX significantly inhibits melanoma both in vitro and in vivo by the combination of CDT, PTT, and CT. In short, our study significantly enhances the effectiveness of transdermal drug delivery by constructing BPMNs and provides a promising novel strategy for transdermal cancer treatment with multiple therapies.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advancements in Transdermal Drug Delivery · Nanoplatforms for cancer theranostics · Photoacoustic and Ultrasonic Imaging

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Key Laboratory of Marine Drugs, Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Shandong Provincial Key laboratory of Glycoscience and Glycoengineering, Qingdao 266003, China

Laboratory for Marine Drugs and Bioproducts of Qingdao National Laboratory for Marine, Science and Technology, Qingdao 266237, China

Funding

National Natural Science Foundation of China · Natural Science Foundation of Shandong Province

References (52)

Show source-provided references
1. 10.1016/j.jaad.2021.12.06610.1016/j.jaad.2021.12.066 ↗
2. 10.1016/S0140-6736(18)31559-910.1016/S0140-6736(18)31559-9 ↗
3. 10.1016/j.ajo.2008.07.04710.1016/j.ajo.2008.07.047 ↗
4. 10.1200/JCO.22.0094410.1200/JCO.22.00944 ↗
5. 10.1021/acs.biomac.1c0169110.1021/acs.biomac.1c01691 ↗
6. 10.1016/j.jconrel.2022.06.02110.1016/j.jconrel.2022.06.021 ↗
7. 10.1021/acsami.1c0965810.1021/acsami.1c09658 ↗
8. 10.1038/nbt.150410.1038/nbt.1504 ↗
9. 10.1517/17425247.2014.87552810.1517/17425247.2014.875528 ↗
10. 10.1021/acs.nanolett.2c0453910.1021/acs.nanolett.2c04539 ↗
11. 10.1016/j.mattod.2021.03.01210.1016/j.mattod.2021.03.012 ↗
12. 10.1016/j.jconrel.2019.10.01610.1016/j.jconrel.2019.10.016 ↗
13. 10.1002/adtp.20180003510.1002/adtp.201800035 ↗
14. 10.1038/s41551-019-0508-y10.1038/s41551-019-0508-y ↗
15. 10.1002/adma.20160404310.1002/adma.201604043 ↗
16. 10.1016/j.actbio.2022.08.06110.1016/j.actbio.2022.08.061 ↗
17. 10.1021/acsami.2c0595210.1021/acsami.2c05952 ↗
18. 10.1021/acsnano.5b0504310.1021/acsnano.5b05043 ↗
19. 10.1038/s41551-018-0337-410.1038/s41551-018-0337-4 ↗
20. 10.1016/j.biomaterials.2018.09.00810.1016/j.biomaterials.2018.09.008 ↗
21. 10.1021/acsbiomaterials.8b0064210.1021/acsbiomaterials.8b00642 ↗
22. 10.1016/j.addr.2021.11398510.1016/j.addr.2021.113985 ↗
23. 10.1021/acsami.1c2041610.1021/acsami.1c20416 ↗
24. 10.1016/j.biomaterials.2023.12208910.1016/j.biomaterials.2023.122089 ↗
25. 10.1021/acsnano.5b0504310.1021/acsnano.5b05043 ↗
26. 10.1016/j.cej.2022.13886410.1016/j.cej.2022.138864 ↗
27. 10.1016/j.actbio.2022.12.07210.1016/j.actbio.2022.12.072 ↗
28. 10.1021/acsnano.2c0733810.1021/acsnano.2c07338 ↗
29. 10.1016/j.actbio.2021.09.00910.1016/j.actbio.2021.09.009 ↗
30. 10.1016/j.cej.2022.13596410.1016/j.cej.2022.135964 ↗
31. 10.1016/j.nantod.2022.10159110.1016/j.nantod.2022.101591 ↗
32. 10.1002/biot.20070005410.1002/biot.200700054 ↗
33. 10.1016/j.carbpol.2013.02.01810.1016/j.carbpol.2013.02.018 ↗
34. 10.1016/j.carbpol.2020.11752910.1016/j.carbpol.2020.117529 ↗
35. 10.1016/j.phrs.2022.10663210.1016/j.phrs.2022.106632 ↗
36. 10.1021/acsnano.0c0008210.1021/acsnano.0c00082 ↗
37. 10.1021/acsnano.1c0917110.1021/acsnano.1c09171 ↗
38. 10.1016/j.jconrel.2022.05.05610.1016/j.jconrel.2022.05.056 ↗
39. 10.1002/advs.20220259110.1002/advs.202202591 ↗
40. 10.1002/adma.20190574010.1002/adma.201905740 ↗
41. 10.1021/acsnano.1c0622510.1021/acsnano.1c06225 ↗
42. 10.1038/nm.218210.1038/nm.2182 ↗
43. 10.1021/acs.nanolett.5b0503010.1021/acs.nanolett.5b05030 ↗
44. 10.1039/C8TB01731J10.1039/C8TB01731J ↗
45. 10.1016/j.eurpolymj.2022.11134010.1016/j.eurpolymj.2022.111340 ↗
46. 10.7150/ntno.7504510.7150/ntno.75045 ↗
47. 10.1038/s41598-022-15239-x10.1038/s41598-022-15239-x ↗
48. 10.1021/ja106855m10.1021/ja106855m ↗
49. 10.1038/s41596-018-0001-110.1038/s41596-018-0001-1 ↗
50. 10.1021/acsnano.1c1023110.1021/acsnano.1c10231 ↗
51. 10.1016/j.bioadv.2022.21272910.1016/j.bioadv.2022.212729 ↗
52. 10.3390/biomedicines906059210.3390/biomedicines9060592 ↗